{'fraction_non_alphanumeric': 0.03697749196141479, 'fraction_numerical': 0.02572347266881029, 'mean_word_length': 5.048543689320389, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 1, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Inhibition of VAP1: Quickly Gaining Ground as an Anti‐Inflammatory Therapy

model, the authors evaluated BBT-2027, a small-molecule inhibitor of SSAO based on a hydrazine derivative developed by BioTie Therapies Corporation. As VAP1 is one of the few proteins that shows SSAO activity in humans, it has quickly become a new target for anti-inflammatory therapy. VAP1 is an ectoenzyme that belongs to the family of semicarbazide-sensitive copper-containing amine oxidases (EC 1.4.3.6) that converts primary amines to aldehydes via oxidative deamination with the concomitant production of H2O2 and ammonia (Figure 1). [4, 5]